208 related articles for article (PubMed ID: 20652971)
21. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway.
Zhang Z; Mao H; Du X; Zhu J; Xu Y; Wang S; Xu X; Ji P; Yu Y; Cao B; Han K; Hou T; Xu Z; Kong Y; Jiang G; Tang X; Qiao C; Mao X
Oncotarget; 2016 Feb; 7(8):9296-308. PubMed ID: 26814430
[TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways.
Kirito K; Watanabe T; Sawada K; Endo H; Ozawa K; Komatsu N
J Biol Chem; 2002 Mar; 277(10):8329-37. PubMed ID: 11756417
[TBL] [Abstract][Full Text] [Related]
23. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract][Full Text] [Related]
24. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
25. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Qian J; Zou Y; Rahman JS; Lu B; Massion PP
Mol Cancer Ther; 2009 Jan; 8(1):101-9. PubMed ID: 19139118
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
27. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
Oshiro MM; Landowski TH; Catlett-Falcone R; Hazlehurst LA; Huang M; Jove R; Dalton WS
Clin Cancer Res; 2001 Dec; 7(12):4262-71. PubMed ID: 11751528
[TBL] [Abstract][Full Text] [Related]
31. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
32. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
33. PI3K/AKT mediated p53 down-regulation participates in CpG DNA inhibition of spontaneous B cell apoptosis.
Zhou Y; Zhen H; Mei Y; Wang Y; Feng J; Xu S; Fu X
Cell Mol Immunol; 2009 Jun; 6(3):175-80. PubMed ID: 19567200
[TBL] [Abstract][Full Text] [Related]
34. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells.
Liu M; Aneja R; Liu C; Sun L; Gao J; Wang H; Dong JT; Sarli V; Giannis A; Joshi HC; Zhou J
J Biol Chem; 2006 Jun; 281(26):18090-7. PubMed ID: 16627469
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway.
Chetoui N; Boisvert M; Gendron S; Aoudjit F
Immunology; 2010 Jul; 130(3):418-26. PubMed ID: 20465565
[TBL] [Abstract][Full Text] [Related]
37. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
38. p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway.
Kumar P; Miller AI; Polverini PJ
J Biol Chem; 2004 Oct; 279(41):43352-60. PubMed ID: 15292252
[TBL] [Abstract][Full Text] [Related]
39. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
40. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
